68% restoration of sensitivity. Xtandi worked much longer, much better, and on many more men than a placebo group. Several CRPC men (some on this site) became resensitive.
It's a breakthrough that is frequently glossed over by the powers that be. I question their transparency or perhaps their ability to understand what this means.
STEP-UP will investigate more and determine if what we have seen in RESTORE and TRANSFORMER are flukes.
The RESTORE trial revealed several key differences between the post-abiraterone and post-enzalutamide cohorts:
PSA50 Responses to BAT:
The PSA50 response rate (≥50% decline in prostate-specific antigen) during BAT was higher in the post-enzalutamide cohort (30%) compared to the post-abiraterone cohort (17%)1.
PSA50 Responses to AR-Targeted Therapy Rechallenge:
After progression on BAT, rechallenge with the prior AR-targeted therapy showed significantly better PSA50 responses in the post-enzalutamide cohort (68%) versus the post-abiraterone cohort (16%, p = 0.001)1.
Time to Progression Following Rechallenge:
The median time from enrollment to progression after rechallenge with AR-targeted therapy was longer in the post-enzalutamide cohort (12.8 months) compared to the post-abiraterone cohort (8.1 months, p = 0.04)1.
These findings suggest that patients who progress on enzalutamide may derive greater benefit from BAT and subsequent rechallenge with AR-targeted therapy compared to those who progress on abiraterone. This could be related to differences in mechanisms of resistance or drug sequencing effects.
FDA Grants Priority Review to Olaparib for HRR-Mutant mCRPC - Targeted Oncology - January 20, 2020
BAT & Nivolumab
Why we add an AART drug to ADT?